125562-30-3

Usage

Uses

Used in Bioconjugation:
m-PEG9-bromide is used as a bioconjugation agent for attaching biologically active molecules to other entities. The bromide group facilitates the coupling process through nucleophilic substitution, while the PEG spacer improves solubility and stability of the resulting conjugates.
Used in Drug Delivery Systems:
In the pharmaceutical industry, m-PEG9-bromide is used as a component in drug delivery systems to improve the solubility, circulation time, and bioavailability of therapeutic agents. The PEG spacer can help reduce immunogenicity and proteolytic degradation, thus enhancing the drug's effectiveness and safety profile.
Used in Polymer Science:
m-PEG9-bromide is utilized as a reactive intermediate in polymer synthesis, allowing for the creation of PEGylated polymers with tailored properties. The bromide group enables the attachment of various functional groups, which can be used to fine-tune the polymer's characteristics for specific applications, such as hydrogels, micelles, or nanoparticles.
Used in Surface Modification:
In materials science, m-PEG9-bromide is employed for surface modification to introduce PEGylated layers onto various substrates. This can lead to improved biocompatibility, reduced protein adsorption, and enhanced resistance to fouling, which are beneficial for applications in medical devices, sensors, and coatings.

Upstream product

• 6048-68-6 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-ol 
• 259226-99-8 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl methanesulfonate 

Downstream Products

• 1233319-98-6 ethyl 6-(2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yloxy)-1-oxo-3-phenyl-1H-indene-2-carboxylate 
• 1233320-04-1 ethyl 1-methylene-6-(2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yloxy)-3-phenyl-1H-indene-2-carboxylate 
• 1233320-01-8 ethyl 1-hydroxy-1-methyl-6-(2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yloxy)-3-phenyl-1H-indene-2-carboxylate 
• 1581723-92-3 mPEG₉-N-metoclopramide 

Relevant academic research and scientific papers

LOW MOLECULAR WEIGHT POLYETHYLENE GLYCOL DRUG CONJUGATES HAVING IMPROVED DRUG BIOLOGICAL ACTIVITY

Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molecules. The conjugates can interact with receptor dimers or polymers, thereby improving the in vivo distribution of the drug, changing the oil and water distribution coefficient, enhancing the pharmacological activity, reducing the blood-brain barrier permeability of the drug, and improving the bioavailability of the drug.

Structure-property relationships in densely grafted π-stacked polymers

Three methyl end-capped oligo(ethylene glycol) (MOEG) ethers (1b-d) and a methoxyderivative (1a) of benzofulvene monomer BFSk were synthesized and induced to polymerize spontaneously by solvent removal to obtain soluble π-stacked polymers bearing densely grafted MOEG side chains (poly-1b-d) and model polymer poly-la. The physicochemical features (e.g., solubility, NMR, MALDI-TOF, and absorption/emission spectra, as well as MWD, conformation plot, and thermal properties) of the synthesized polymers were compared in a structure-property relationship study. This approach afforded the following evidence. The structure of poly-1a-d is very similar to that of BF3k, suggesting that the polymerization mechanism is not affected by the presence of the electron-rich methoxy group or bulkier MOEG side chains. However, the latter appear to be capable of affecting the conformational behavior of the polymer backbone. The solubility of poly-1a-d depends on the number of the oligo (ethylene glycol) monomeric units. In particular, poly-1d, featuring a long MOEG side chain (n = 9), shows an amphophilic character and is soluble in a number of organic solvents, whereas it interacts with water to give isolated macromolecules in equilibrium with nanosized water-soluble aggregates. 2010 Wiley Periodicals, Inc.

Platinum(II) complexes, their preparation and use as anti-tumor agents

Compounds of formula I STR1 wherein R1 and R2, that can be the same or different, are hydrogen, alkyl, aryl, aralkyl groups or, if taken together, cycloalkyl groups; A is a carbon atom, a residue of 2,3-dioxybutandioic-2,4-dioxyphtalic acid or disubstituted malonic acid derivatives; n1 and n2 are selected in such a manner that the result of their addition is from 2 to 40; T1 and T2 that can be the same or different, are hydrogen, alkyl, benzyl, phenyl, acyl or cycloalkyl or a residue of formulae STR2 Compounds I are useful as anti-tumor agents in human therapy.